Related Experiment Video
Updated: May 22, 2026
11:29
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Analysis of IMP3 expression in prostate adenocarcinomas
Hülya Tosun Yildirim1, Nilay Sentürk
1Department of Medical Pathology, Pamukkale University, Faculty of Medicine, Denizli, Turkey. drhulyatosun@gmail.com
Turk Patoloji Dergisi
|May 26, 2012
Summary
Insulin-Like Growth Factor II protein expression was not found in prostate adenocarcinoma, high-grade PIN, or benign prostate glands. Therefore, Insulin-Like Growth Factor II is not involved in prostate cancer development or diagnosis.
Area of Science:
- Oncology
- Molecular Biology
- Urology
Background:
- Prostate cancer is a leading cause of male cancer deaths globally.
- Established prognostic factors for prostate carcinoma include PSA levels, TNM staging, histological grade, and surgical margins.
- Insulin-Like Growth Factor II (IGF-II) is an oncofetal protein linked to aggressive tumor behavior in various cancers.
Purpose of the Study:
- To investigate the expression of Insulin-Like Growth Factor II in benign prostate glands, high-grade prostatic intraepithelial neoplasia (PIN), and prostate adenocarcinoma.
- To determine the potential role of Insulin-Like Growth Factor II in the pathogenesis of prostate adenocarcinoma.
Main Methods:
- Immunohistochemistry was employed to assess Insulin-Like Growth Factor II expression.
- The study included 70 cases of prostate adenocarcinoma, along with associated high-grade PIN and benign prostate glands.
Main Results:
- Insulin-Like Growth Factor II expression was undetectable in all evaluated prostate adenocarcinoma, high-grade PIN, and benign prostate gland samples.
- No correlation was found between Insulin-Like Growth Factor II expression and the presence of prostate adenocarcinoma or its precursor lesions.
Conclusions:
- The findings suggest that Insulin-Like Growth Factor II protein expression is not implicated in the pathogenesis of prostate adenocarcinomas.
- Insulin-Like Growth Factor II expression status is unlikely to serve as a diagnostic marker for prostate adenocarcinomas, despite the study's limited case numbers.
